1. Chronic disease: an economic perspective;Suhrcke,2006
2. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas;El Khoury;J Med Econ,2012
3. Access to costly new hepatitis C drugs: medicine, money, and Advocacy;Trooskin;Clin Infect Dis,2015
4. Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature;San Miguel;Expert Rev Pharmacoecon Outcomes Res,2014
5. The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: are the new all-oral regimens good value to society?;Younossi;Liver Int,2016